Like inflammation, fibrosis is a downstream effect of the lack of dystrophin and occurs as chronic inflammation that prevents muscle repair. Fibrosis is defined as the thickening and scarring of connective tissue, usually as a result of injury. This panel will discuss therapies that aim to reduce fibrosis and inflammation by decreasing the breakdown of mature muscle cells and increasing muscle strength.

Panelists:
FibroGen (Bassem Elmankabadi, MD, Executive Medical supervisor, Global Clinical Development Lead)
Italfarmaco (Paolo Bettica, MD, PhD, CMO)
Capricor (Linda Marban, PhD CEO)
Followed by discussion and Q &A